The DOI matches its Crossref record; 193 of the 193 references it cites were found in a registry or an index.
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Han, C. L., Michalopoulos, G. K., & Wu, T. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20560 · Cited by 129
RetractedMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
Smad-dependent and Smad-independent pathways in TGF-β family signalling
Derynck, R., & Zhang, Y. E. (2003) · Nature · doi:10.1038/nature02006 · Cited by 5,373
Mammalian MAP kinase signalling cascades
Chang, L., & Karin, M. (2001) · Nature · doi:10.1038/35065000 · Cited by 5,111
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
JONES, J. I., & CLEMMONS, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,710
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
MECHANISMS OF WNT SIGNALING IN DEVELOPMENT
Wodarz, A., & Nusse, R. (1998) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.14.1.59 · Cited by 2,017
Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling
Nakao, A., Afrakhte, M., Morn, A., Nakayama, T., Christian, J. L., Heuchel, R., Itoh, S., Kawabata, M., Heldin, N.-E., Heldin, C.-H., et al. (1997) · Nature · doi:10.1038/39369 · Cited by 1,809
Cellular Actions of the Insulin-Like Growth Factor Binding Proteins
Firth, S. M., & Baxter, R. C. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0033 · Cited by 1,750
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“There are also multiple interactions of growth factor signaling pathways with p53, a central regulator of apoptosis, cell cycle and genomic stability (reviewed by Sherr and McCormick, 2002).”
BackgroundInman, G. J., Nicolás, F. J., Callahan, J. F., Harling, J. D., Gaster, L. M., Reith, A. D., Laping, N. J., & Hill, C. S. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.65 · Cited by 1,634
Scatter factor/hepatocyte growth factor is essential for liver development
Schmidt, C., Bladt, F., Goedecke, S., Brinkmann, V., Zschiesche, W., Sharpe, M., Gherardi, E., & Birchmeler, C. (1995) · Nature · doi:10.1038/373699a0 · Cited by 1,394
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Smad7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGFβ Receptor for Degradation
Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., & Wrana, J. L. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00134-9 · Cited by 1,205
Somatic mutations of the β-catenin gene are frequent in mouse and human hepatocellular carcinomas
Coste, A. D. L., Romagnolo, B., Billuart, P., Renard, C.-A., Buendia, M.-A., Soubrane, O., Fabre, M., Chelly, J., Beldjord, C., Kahn, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8847 · Cited by 1,121
A mechanism of repression of TGFbeta / Smad signaling by oncogenic Ras
Kretzschmar, M., Doody, J., Timokhina, I., & Massague, J. (1999) · Genes & Development · doi:10.1101/gad.13.7.804 · Cited by 1,004
Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., Arteaga, C. L., & Moses, H. L. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.1.27 · Cited by 1,004
Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L., & Arteaga, C. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005912200 · Cited by 992
Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., et al. (2000) · Nature Genetics · doi:10.1038/73448 · Cited by 960
Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R., Costantino, A., Goldfine, I. D., Belfiore, A., & Vigneri, R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3278 · Cited by 902
A small molecule inhibitor of β-catenin/cyclic AMP response element-binding protein transcription
Emami, K. H., Nguyen, C., Ma, H., Kim, D. H., Jeong, K. W., Eguchi, M., Moon, R. T., Teo, J.-L., Oh, S. W., Kim, H. Y., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404875101 · Cited by 874
Induction of the growth inhibitor IGF-binding protein 3 by p53
Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., & Kley, N. (1995) · Nature · doi:10.1038/377646a0 · Cited by 869
MEMBRANE-ANCHORED GROWTH FACTORS
Massagué, J., & Pandiella, A. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002503 · Cited by 660
Small-molecule antagonists of the oncogenic Tcf/β-catenin protein complex
Lepourcelet, M., Chen, Y.-N. P., France, D. S., Wang, H., Crews, P., Petersen, F., Bruseo, C., Wood, A. W., & Shivdasani, R. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00334-9 · Cited by 653
Hepatocellular Carcinoma: An Epidemiologic View
El-Serag, H. B. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200211002-00002 · Cited by 633
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Akiyama, M., Hideshima, T., Chauhan, D., Joseph, M., Libermann, T. A., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00050-9 · Cited by 614
Matsuzawa, S.-I., & Reed, J. C. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00242-8 · Cited by 587
Smad4 and FAST-1 in the assembly of activin-responsive factor
Chen, X., Weisberg, E., Fridmacher, V., Watanabe, M., Naco, G., & Whitman, M. (1997) · Nature · doi:10.1038/38008 · Cited by 565
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00051-0 · Cited by 542
Mead, J. E., & Fausto, N. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.5.1558 · Cited by 526
Feng, X.-H., Zhang, Y., Wu, R.-Y., & Derynck, R. (1998) · Genes & Development · doi:10.1101/gad.12.14.2153 · Cited by 525
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
Met provides essential signals for liver regeneration
Borowiak, M., Garratt, A. N., Wüstefeld, T., Strehle, M., Trautwein, C., & Birchmeier, C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403412101 · Cited by 497
Mutational spectrum of β-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas
Taniguchi, K., Roberts, L. R., Aderca, I. N., Dong, X., Qian, C., Murphy, L. M., Nagorney, D. M., Burgart, L. J., Roche, P. C., Smith, D. I., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205591 · Cited by 486
Ryo, A., Nakamura, M., Wulf, G., Liou, Y.-C., & Lu, K. P. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-793 · Cited by 465
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 462
Dual role of the Smad4/DPC4 tumor suppressor in TGFβ-inducible transcriptional complexes
Liu, F., Pouponnot, C., & Massagué, J. (1997) · Genes & Development · doi:10.1101/gad.11.23.3157 · Cited by 445
IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms
Mohan, S., & Baylink, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750019 · Cited by 444
The IGF-I receptor in cell growth, transformation and apoptosis
Baserga, R., Hongo, A., Rubini, M., Prisco, M., & Valentinis, B. (1997) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(97)00007-3 · Cited by 439
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
Bakin, A. V., Rinehart, C., Tomlinson, A. K., & Arteaga, C. L. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.15.3193 · Cited by 431
Liu, J., Stevens, J., Rote, C. A., Yost, H. J., Hu, Y., Neufeld, K. L., White, R. L., & Matsunami, N. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00241-6 · Cited by 422
A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00567-0 · Cited by 420
DaCosta Byfield, S., Major, C., Laping, N. J., & Roberts, A. B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.744 · Cited by 414
Uhl, M., Aulwurm, S., Wischhusen, J., Weiler, M., Ma, J. Y., Almirez, R., Mangadu, R., Liu, Y.-W., Platten, M., Herrlinger, U., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1013 · Cited by 414
Sunnarborg, S. W., Hinkle, C. L., Stevenson, M., Russell, W. E., Raska, C. S., Peschon, J. J., Castner, B. J., Gerhart, M. J., Paxton, R. J., Black, R. A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112050200 · Cited by 413
Cohen, B. D., Baker, D. A., Soderstrom, C., Tkalcevic, G., Rossi, A. M., Miller, P. E., Tengowski, M. W., Wang, F., Gualberto, A., Beebe, J. S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1070 · Cited by 365
Cyclolignans as Inhibitors of the Insulin-Like Growth Factor-1 Receptor and Malignant Cell Growth
Girnita, A., Girnita, L., Prete, F. D., Bartolazzi, A., Larsson, O., & Axelson, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2522 · Cited by 363
M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity
De Souza, A. T., Hankins, G. R., Washington, M. K., Orton, T. C., & Jirtle, R. L. (1995) · Nature Genetics · doi:10.1038/ng1295-447 · Cited by 355
Wong, C. M., Fan, S. T., & Ng, I. O. L. (2001) · Cancer · doi:10.1002/1097-0142(20010701)92:1<136::aid-cncr1301>3.0.co;2-r · Cited by 348
Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells*
Jo, M., Stolz, D. B., Esplen, J. E., Dorko, K., Michalopoulos, G. K., & Strom, S. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8806 · Cited by 347
Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M., Miyazono, K., Node, M., & Imamura, T. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00103.x · Cited by 339
Trojan, J., Johnson, T. R., Rudin, S. D., Ilan, J., Tykocinski, M. L., & Ilan, J. (1993) · Science · doi:10.1126/science.8418502 · Cited by 329
Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M., Higashiyama, S., Noda, K., Miyoshi, E., Monden, M., & Matsuura, N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1580 · Cited by 321
ZD1839 (???Iressa???)*,??? as an Anticancer Agent
Baselga, J., & Averbuch, S. D. (2000) · Drugs · doi:10.2165/00003495-200060001-00004 · Cited by 301
Scotlandi, K., Manara, M. C., Nicoletti, G., Lollini, P.-L., Lukas, S., Benini, S., Croci, S., Perdichizzi, S., Zambelli, D., Serra, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3192 · Cited by 299
Nhieu, J. T. V., Renard, C. A., Wei, Y., Cherqui, D., Zafrani, E. S., & Buendia, M. A. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65168-1 · Cited by 295
Hsu, H.-C., Jeng, Y.-M., Mao, T.-L., Chu, J.-S., Lai, P.-L., & Peng, S.-Y. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64590-7 · Cited by 294
Halder, S. K., Beauchamp, R. D., & Datta, P. K. (2005) · Neoplasia · doi:10.1593/neo.04640 · Cited by 288
Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells
Miyoshi, A., Kitajima, Y., Sumi, K., Sato, K., Hagiwara, A., Koga, Y., & Miyazaki, K. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601685 · Cited by 284
Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., & Bishop, J. M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.5.1023 · Cited by 281
Tumor formation by genetic mutations in the components of the Wnt signaling pathway
Kikuchi, A. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01424.x · Cited by 260
Essential Role of Gab1 for Signaling by the C-Met Receptor in Vivo
Sachs, M., Brohmann, H., Zechner, D., Müller, T., Hülsken, J., Walther, I., Schaeper, U., Birchmeier, C., & Birchmeier, W. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.150.6.1375 · Cited by 258
Giannelli, G., Bergamini, C., Fransvea, E., Sgarra, C., & Antonaci, S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.055 · Cited by 252
Targeting HER1/EGFR: A molecular approach to cancer therapy
Arteaga, C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00185-4 · Cited by 251
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma
Merle, P., de la Monte, S., Kim, M., Herrmann, M., Tanaka, S., Von Dem Bussche, A., Kew, M. C., Trepo, C., & Wands, J. R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.009 · Cited by 249
Insulin‐like growth factor ligands, receptors, and binding proteins in cancer
Foulstone, E., Prince, S., Zaccheo, O., Burns, J., Harper, J., Jacobs, C., Church, D., & Hassan, A. (2005) · The Journal of Pathology · doi:10.1002/path.1712 · Cited by 245
Kato, H., Faria, T. N., Stannard, B., Roberts, C. T., & LeRoith, D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53824-2 · Cited by 243
Bohula, E. A., Salisbury, A. J., Sohail, M., Playford, M. P., Riedemann, J., Southern, E. M., & Macaulay, V. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300714200 · Cited by 237
Promoter-specific imprinting of the human insulin-like growth factor-II gene
Vu, T. H., & Hoffman, A. R. (1994) · Nature · doi:10.1038/371714a0 · Cited by 227
TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G1 arrest
Petritsch, C., Beug, H., Balmain, A., & Oft, M. (2000) · Genes & Development · doi:10.1101/gad.854200 · Cited by 223
TGF‐β control of cell proliferation
Huang, S. S., & Huang, J. S. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20558 · Cited by 219
Epidermal Growth Factor Receptor: A Novel Target of the Wnt/β-Catenin Pathway in Liver
Tan, X., Apte, U., Micsenyi, A., Kotsagrelos, E., Luo, J.-H., Ranganathan, S., Monga, D. K., Bell, A., Michalopoulos, G. K., & Monga, S. P. S. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.013 · Cited by 219
Bedossa, P., Peltier, E., Terris, B., Franco, D., & Poynard, T. (1995) · Hepatology · doi:10.1002/hep.1840210325 · Cited by 215
McCawley, L. J., O'Brien, P., & Hudson, L. G. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199808)176:2<255::aid-jcp4>3.0.co;2-n · Cited by 215
Párrizas, M., Gazit, A., Levitzki, A., Wertheimer, E., & LeRoith, D. (1997) · Endocrinology · doi:10.1210/en.138.4.1427 · Cited by 212
Matsuzawa, S.-I. (1998) · The EMBO Journal · doi:10.1093/emboj/17.10.2736 · Cited by 203
LIU, X., SUN, Y., WEINBERG, R., & LODISH, H. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00031-9 · Cited by 197
The development and clinical use of trastuzumab (Herceptin).
Harries, M., & Smith, I. (2002) · Endocrine-related cancer · doi:10.1677/erc.0.0090075 · Cited by 196
The Wnt connection to tumorigenesis
Behrens, J., & Lustig, B. (2004) · The International Journal of Developmental Biology · doi:10.1387/ijdb.041815jb · Cited by 194
Boon, E. M. J., Keller, J. J., Wormhoudt, T. A. M., Giardiello, F. M., Offerhaus, G. J. A., van der Neut, R., & Pals, S. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601505 · Cited by 190
Gotzmann, J., Huber, H., Thallinger, C., Wolschek, M., Jansen, B., Schulte-Hermann, R., Beug, H., & Mikulits, W. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.6.1189 · Cited by 185
Warshamana-Greene, G. S., Litz, J., Buchdunger, E., García-Echeverría, C., Hofmann, F., & Krystal, G. W. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1544 · Cited by 184
Cross-talk between the proto-oncogenes Met and Ron
Follenzi, A., Bakovic, S., Gual, P., Stella, M. C., Longati, P., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203620 · Cited by 183
Berthou, S., Aebersold, D. M., Schmidt, L. S., Stroka, D., Heigl, C., Streit, B., Stalder, D., Gruber, G., Liang, C., Howlett, A. R., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207691 · Cited by 178
Hjelmeland, M. D., Hjelmeland, A. B., Sathornsumetee, S., Reese, E. D., Herbstreith, M. H., Laping, N. J., Friedman, H. S., Bigner, D. D., Wang, X.-F., & Rich, J. N. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.737.3.6 · Cited by 177
Trojan, J., Blossey, B. K., Johnson, T. R., Rudin, S. D., Tykocinski, M., Ilan, J., & Ilan, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.4874 · Cited by 176
Höpfner, M., Sutter, A. P., Huether, A., Schuppan, D., Zeitz, M., & Scherübl, H. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.08.024 · Cited by 173
Kern, M. (2002) · Hepatology · doi:10.1016/s0270-9139(02)00094-0 · Cited by 170
Moinzadeh, P., Breuhahn, K., Stützer, H., & Schirmacher, P. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602448 · Cited by 169
Self-citationDickkopf-3/REIC functions as a suppressor gene of tumor growth
Hsieh, S.-Y., Hsieh, P.-S., Chiu, C.-T., & Chen, W.-Y. (2004) · Oncogene · doi:10.1038/sj.onc.1208138 · Cited by 168
Smad2 and Smad4 gene mutations in hepatocellular carcinoma
Yakicier, M. C., Irmak, M. B., Romano, A., Kew, M., & Ozturk, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202866 · Cited by 167
Huether, A., Höpfner, M., Sutter, A. P., Schuppan, D., & Scherübl, H. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.02.040 · Cited by 167
Neaud, V, Faouzi, S., Guirouilh, J., Le Bail, B., Balabaud, C., Bioulac-Sage, P., & Rosenbaum, J. (1997) · Hepatology · doi:10.1002/hep.510260612 · Cited by 167
Huether, A., Höpfner, M., Baradari, V., Schuppan, D., & Scherübl, H. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.09.007 · Cited by 166
Type-2 IGF Receptor: A Multi-Ligand Binding Protein
Braulke, T. (1999) · Hormone and Metabolic Research · doi:10.1055/s-2007-978725 · Cited by 166
CI-1033, a pan-erbB tyrosine kinase inhibitor
SLICHENMYER, W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90285-4 · Cited by 165
Paumelle, R., Tulashe, D., Kherrouche, Z., Plaza, S., Leroy, C., Reveneau, S., Vandenbunder, B., & Fafeur, V. (2002) · Oncogene · doi:10.1038/sj.onc.1205297 · Cited by 158
Shibata, T., Chuma, M., Kokubu, A., Sakamoto, M., & Hirohashi, S. (2003) · Hepatology · doi:10.1053/jhep.2003.50270 · Cited by 154
Vasilcanu, D., Girnita, A., Girnita, L., Vasilcanu, R., Axelson, M., & Larsson, O. (2004) · Oncogene · doi:10.1038/sj.onc.1208065 · Cited by 152
Substrate Competitive Inhibitors of IGF-1 Receptor Kinase
Blum, G., Gazit, A., & Levitzki, A. (2000) · Biochemistry · doi:10.1021/bi001516y · Cited by 151
Daveau, M., Scotté, M., François, A., Coulouarn, C., Ros, G., Tallet, Y., Hiron, M., Hellot, M., & Salier, J. (2003) · Molecular Carcinogenesis · doi:10.1002/mc.10103 · Cited by 146
Menu, E., Jernberg‐Wiklund, H., Strömberg, T., Raeve, H. D., Girnita, L., Larsson, O., Axelson, M., Asosingh, K., Nilsson, K., Camp, B. V., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0293 · Cited by 145
Wirths, O., Waha, A., Weggen, S., Schirmacher, P., Kühne, T., Goodyer, C. G., Albrecht, S., von Schweinitz, D., & Pietsch, T. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000059926.66359.bd · Cited by 141
Self-citationCivenni, G., Holbro, T., & Hynes, N. E. (2003) · EMBO Reports · doi:10.1038/sj.embor.embor735 · Cited by 134
Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma
Abou-Shady, M. A., Baer, H. U., Friess, H., Berberat, P. O., Zimmermann, A., Graber, H. U., Gold, L. I., Korc, M., & Büchler, M. W. (1999) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)00012-4 · Cited by 133
Goya, M., Miyamoto, S., Nagai, K., Ohki, Y., Nakamura, K., Shitara, K., Maeda, H., Sangai, T., Kodama, K., Endoh, Y., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0919 · Cited by 131
Cyclooxygenase-2 in hepatocellular carcinoma
Wu, T. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.10.004 · Cited by 130
Breuhahn, K., Vreden, S., Haddad, R., Beckebaum, S., Stippel, D. L., Flemming, P., Nussbaum, T., Caselmann, W. H., Haab, B. B., & Schirmacher, P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0292 · Cited by 129
Self-citationExpression of the C– Met Protooncogene in Human Hepatocellular Carcinoma
Suzuki, K., Hayashi, N., Yamada, Y., Yoshihara, H., Miyamoto, Y., Ito, Y., Ito, T., Katayama, K., Sasaki, Y., Ito, A., et al. (1994) · Hepatology · doi:10.1002/hep.1840200520 · Cited by 125
c-met mRNA overexpression in human hepatocellular carcinoma
Boix, L., Rosa, J. L., Ventura, F., Castells, A., Bruix, J., Rodés, J., & Bartrons, R. (1994) · Hepatology · doi:10.1002/hep.1840190115 · Cited by 124
Suzuki, A., Hayashida, M., Kawano, H., Sugimoto, K., Nakano, T., & Shiraki, K. (2000) · Hepatology · doi:10.1053/jhep.2000.17738 · Cited by 123
Transforming growth factor‐β1 as a useful serologic marker of small hepatocellular carcinoma
Song, B., Chung, Y., Kim, J. A., Choi, W.-B., Suh, D. D., Pyo, S. I., Shin, J. W., Lee, H. C., Lee, Y. S., & Suh, D. J. (2001) · Cancer · doi:10.1002/cncr.10170 · Cited by 120
Development of New Insulin-like Growth Factor-1 Receptor Kinase Inhibitors Using Catechol Mimics
Blum, G., Gazit, A., & Levitzki, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305490200 · Cited by 120
Nath, N., Kashfi, K., Chen, J., & Rigas, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2134840100 · Cited by 118
Hepatocyte growth factor/scatter factor‐induced intracellular signalling
Stuart, K. A., Riordan, S. M., Lidder, S., Crostella, L., Williams, R. L., & Skouteris, G. G. (2000) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2000.00138.x · Cited by 116
Johnson, M., Koukoulis, G. Κ., Matsumoto, K., Nakamura, T., & Iyer, A. (1993) · Hepatology · doi:10.1002/hep.1840170618 · Cited by 115
Nishiyama, M., & Wands, J. R. (1992) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(92)91640-c · Cited by 114
The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor
Ohmichi, M., Pang, L., Ribon, V., Gazit, A., Levitzki, A., & Saltiel, A. R. (1993) · Biochemistry · doi:10.1021/bi00068a024 · Cited by 113
APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis
Ficari, F., Cama, A., Valanzano, R., Curia, M. C., Palmirotta, R., Aceto, G. M., Esposito, D. L., Crognale, S., Lombardi, A., Messerini, L., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0925 · Cited by 112
Prange, W., Breuhahn, K., Fischer, F. F., Zilkens, C., Pietsch, T., Petmecky, K., Eilers, R., Dienes, H., & Schirmacher, P. (2003) · The Journal of Pathology · doi:10.1002/path.1448 · Cited by 112
Self-citationAspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells
Abiru, S., Nakao, K., Ichikawa, T., Migita, K., Shigeno, M., Sakamoto, M., Ishikawa, H., Hamasaki, K., Nakata, K., & Eguchi, K. (2002) · Hepatology · doi:10.1053/jhep.2002.32676 · Cited by 111
Hayashi, T., Hideshima, T., Nguyen, A. N., Munoz, O., Podar, K., Hamasaki, M., Ishitsuka, K., Yasui, H., Richardson, P., Chakravarty, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0632 · Cited by 110 · cited 1×
“Equally, SD-208 inhibits TGFb-mediated migration and invasion; however, viability and proliferation are not reduced in all the tumor cell models studied so far (Hayashi et al., 2004; Uhl et al., 2004).”
Backgroundp53 mutation as a source of aberrant β-catenin accumulation in cancer cells
Cagatay, T., & Ozturk, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205919 · Cited by 110
Tavian, D., Petro, G. D., Benetti, A., Portolani, N., Giulini, S. M., & Barlati, S. (2000) · International Journal of Cancer · Cited by 110
Structure-function relationship of the insulin-like growth factor-I receptor tyrosine kinase.
Grønborg, M., Wulff, B. S., Rasmussen, J. S., Kjeldsen, T., & Gammeltoft, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49481-7 · Cited by 109
Cui, J., Zhou, X., Liu, Y., Tang, Z., & Romeih, M. H. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.02973.x · Cited by 109
Pang, R. W. C., Yuen, J., Yuen, M., Lai, C., Lee, T. K., Man, K., Poon, R. T. P., Fan, S. T., Wong, C., Ng, I. O., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207493 · Cited by 106
Popolo, A. D., Memoli, A., Apicella, A., Tuccillo, C., Palma, A. M. D., Ricchi, P., Acquaviva, A. M., & Zarrilli, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203952 · Cited by 105
Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the β-catenin signaling activity
Zhou, L., An, N., Haydon, R. C., Zhou, Q., Cheng, H., Peng, Y., Jiang, W., Luu, H. H., Vanichakarn, P., Szatkowski, J. P., et al. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00013-2 · Cited by 104
Devereux, T. R., Stern, M. C., Flake, G. P., Yu, M. C., Zhang, Z., London, S. J., & Taylor, J. A. (2001) · Molecular Carcinogenesis · doi:10.1002/mc.1041 · Cited by 103
Martin, D. C., Fowlkes, J. L., Babic, B., & Khokha, R. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.4.881 · Cited by 101
More Than One Way to Skin a Catenin
Polakis, P. G. (2001) · Cell · doi:10.1016/s0092-8674(01)00379-8 · Cited by 101
Insulin-like growth factor-binding proteins: functional diversity or redundancy?
Murphy, L. (1998) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0210097 · Cited by 101
Insulin-like growth factor 1 and hair growth
Su, H.-Y., Hickford, J. G. H., Palmer, B. R., & Bickerstaffe, R. (1999) · Dermatology Online Journal · doi:10.5070/d32v79r893 · Cited by 100
西山, 正. (1994) · Medical Entomology and Zoology · doi:10.11501/3096694 · Cited by 100
Hov, H., Holt, R. U., Rø, T. B., Fagerli, U., Hjorth‐Hansen, H., Baykov, V., Christensen, J. G., Waage, A., Sundan, A., & Børset, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0874 · Cited by 97
Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma
Inui, Y., Higashiyama, S., Kawata, S., Tamura, S., Miyagawa, J.-I., Taniguchi, N., & Matsuzawa, Y. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90823-0 · Cited by 96
Lee, Y. I., Lee, S., Das, G. C., Park, U. S., Park, S. M., & Lee, Y. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203694 · Cited by 94
Okumoto, K., Hattori, E., Tamura, K., Kiso, S., Watanabe, H., Saito, K., Saito, T., Togashi, H., & Kawata, S. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00882.x · Cited by 93
Overexpression of Insulin Receptor Substrate-2 in Human and Murine Hepatocellular Carcinoma
Boissan, M., Beurel, E., Wendum, D., Rey, C., Lécluse, Y., Housset, C., Lacombe, M., & Desbois‐Mouthon, C. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62058-5 · Cited by 93
Yau, T.-O., Chan, C., Chan, K., Lee, M.-F., Wong, C., Fan, S.-T., & Ng, I. O. (2004) · Oncogene · doi:10.1038/sj.onc.1208340 · Cited by 93
Adachi, Y., Lee, C., Coffee, K. A., Yamagata, N., Ohm, J. E., Park, K., Dikov, M. M., Nadaf, S., Arteaga, C. L., & Carbone, D. P. (2002) · Gastroenterology · doi:10.1053/gast.2002.36023 · Cited by 88
Feedback regulation of MAPK signalling by an RNA-binding protein
Sugiura, R., Kita, A., Shimizu, Y., Shuntoh, H., Sio, S. O., & Kuno, T. (2003) · Nature · doi:10.1038/nature01907 · Cited by 84
Seol, D., Chen, Q., & Zarnegar, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203404 · Cited by 82
Jiang, Y., Xu, W., Lü, J., He, F., & Yang, X. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5521 · Cited by 81
Sue, S. R., Chari, R. S., Kong, F., Mills, J. J., Fine, R. L., Jirtle, R. L., & Meyers, W. C. (1995) · Annals of Surgery · doi:10.1097/00000658-199508000-00009 · Cited by 81
Rescan, C., Coutant, A., Talarmin, H., Théret, N., Glaise, D., Guguen‐Guillouzo, C., & Baffet, G. (2001) · Molecular Biology of the Cell · doi:10.1091/mbc.12.3.725 · Cited by 80
Byrd, J. C., Devi, G. R., Souza, A. T. D., Jirtle, R. L., & MacDonald, R. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24408 · Cited by 80
Lee, Y. I., Lee, S., Lee, Y. I., Bong, Y., Hyun, S. W., Yoo, Y. D., Kim, S., Kim, Y. W., & Poo, H. R. (1998) · Oncogene · doi:10.1038/sj.onc.1201760 · Cited by 80
Sato, C., Tsuboi, R., Shi, C., Rubin, J. S., & Ogawa, H. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12606221 · Cited by 79
Interaction of the Monoclonal AntibodiesαlR-1 andαIR-3 with Insulin and Somatomedin-C Receptors
Jacobs, S., COOK, S., Svoboda, M. E., & Wyk, J. J. V. (1986) · Endocrinology · doi:10.1210/endo-118-1-223 · Cited by 77
Weihrauch, M., Benicke, M., Lehnert, G., Wittekind, C., Wrbitzky, R., & Tannapfel, A. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1675 · Cited by 77
Monvoisin, A., Bisson, C., Si‐Tayeb, K., Balabaud, C. P., Desmoulière, A., & Rosenbaum, J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1595 · Cited by 77
Cheng, P., Chang, M.-H., Chao, C.-H., & Lee, Y. W. (2004) · Oncogene · doi:10.1038/sj.onc.1208066 · Cited by 72
Studies of ligand-induced site-specific phosphorylation of epidermal growth factor receptor
Guo, L., Kozlosky, C. J., Ericsson, L. H., Daniel, T. O., Cerretti, D. P., & Johnson, R. S. (2003) · Journal of the American Society for Mass Spectrometry · doi:10.1016/s1044-0305(03)00206-x · Cited by 67
Monvoisin, A., Neaud, V., de Lédinghen, V., Dubuisson, L., Balabaud, C. P., Bioulac‐Sage, P., Desmoulière, A., & Rosenbaum, J. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80113-5 · Cited by 67
M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in Japan
Oka, Y., Waterland, R. A., Killian, J. K., Nolan, C. M., Jang, H.-S., Tohara, K., Sakaguchi, S., Yao, T., Iwashita, A., Yata, Y., et al. (2002) · Hepatology · doi:10.1053/jhep.2002.32669 · Cited by 65
Miyamoto, S., Nakamura, M., Shitara, K., Nakamura, K., Ohki, Y., Ishii, G., Goya, M., Kodama, K., Sangai, T., Maeda, H., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1701 · Cited by 63
Nardone, G., Romano, M., Calabrò, A., Pedone, P. V., de Sio, I., Persico, M., Budillon, G., Bruni, C. B., Riccio, A., & Zarrilli, R. (1996) · Hepatology · doi:10.1002/hep.510230602 · Cited by 62
Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling
Zhang, T., Ma, J., & Cao, X. (2003) · Biochemical Journal · doi:10.1042/bj20030668 · Cited by 60
Negative regulation of ErbB family receptor tyrosine kinases
Sweeney, C. A., & Carraway, K. L. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601500 · Cited by 57
Noguchi, O., Enomoto, N., Ikeda, T., Kobayashi, F., Marumo, F., & Sato, C. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80006-7 · Cited by 56
Lund, P., Schubert, D., Niketeghad, F., & Schirmacher, P. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.10.018 · Cited by 53
Self-citationThe expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma
Gong, Y., Cui, L., & Minuk, G. Y. (2000) · Molecular and Cellular Biochemistry · doi:10.1023/a:1007010818094 · Cited by 52
Efficacy of Wnt-1 monoclonal antibody in sarcoma cells
Mikami, I., You, L., He, B., Xu, Z., Batra, S., Lee, A. Y., Mazières, J., Reguart, N., Uematsu, K., Koizumi, K., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-53 · Cited by 52
Yuen, M., Norris, S. A., Evans, L. W., Langley, P. G., & Hughes, R. D. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655202753416939 · Cited by 52
Lee, S., 박의순, & Lee, Y. I. (2001) · Virology · doi:10.1006/viro.2001.0892 · Cited by 51
Fan, G., Ma, X., Wong, P., Rodrigues, C. M. P., & Steer, C. J. (2004) · APOPTOSIS · doi:10.1023/b:appt.0000018803.11260.02 · Cited by 50
Sedlaczek, N., Hasilík, A., Neuhaus, P., Schuppan, D., & Herbst, H. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600777 · Cited by 48
Ефимова, Е. А., Glanemann, M., Liu, L., Schumacher, G., Settmacher, U., Jonas, S., Langrehr, J. M., Neuhaus, P., & Nussler, A. K. (2004) · European Surgical Research · doi:10.1159/000079915 · Cited by 47
SIAH1 inactivation correlates with tumor progression in hepatocellular carcinomas
Matsuo, K., Satoh, S., Okabe, H., Nomura, A., Maeda, T., Yamaoka, Y., & Ikai, I. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10170 · Cited by 47
Esposito, D. L., Blakesley, V. A., Koval, A. P., Scrimgeour, A. G., & LeRoith, D. (1997) · Endocrinology · doi:10.1210/en.138.7.2979 · Cited by 45
Activation of the IGF-II Gene by HBV-X Protein Requires PKC and p44/p42 Map Kinase Signalings
Kang-Park, S., Lee, J., Shin, J.-H., & Lee, Y. I. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4767 · Cited by 42
Tsai, J., Chuang, L., Jeng, J., Yang, M., Chang, W., HSIEH, M.-Y., Lin, Z., & TSAI, J.-H. (1997) · Medicine · doi:10.1097/00005792-199705000-00007 · Cited by 41
Expression of hepatocyte growth factor in human hepatocellular carcinoma
Guirouilh‐Barbat, J., Bail, B. L., Boussarie, L., Balabaud, C. P., Bioulac‐Sage, P., Desmoulière, A., Schuppan, D., & Rosenbaum, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00014-3 · Cited by 39
Selden, C., Farnaud, S., Ding, S. F., Habib, N. A., Foster, C. S., & Hodgson, H. J. F. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80400-3 · Cited by 38
Ozaki, I. (2003) · Hepatology Research · doi:10.1016/s1386-6346(03)00268-7 · Cited by 36
Sakai, K., & Clemmons, D. R. (2003) · Endocrinology · doi:10.1210/en.2002-221133 · Cited by 35
Vernucci, M., Cerrato, F., Besnard, N., Casola, S. S., Pedone, P. V., Bruni, C. B., & Riccio, A. (2000) · Oncogene · doi:10.1038/sj.onc.1204024 · Cited by 34
Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?
Musgrove, E. A. (2003) · Breast Cancer Research · doi:10.1186/bcr737 · Cited by 33
Grasl‐Kraupp, B., Schausberger, E., Hufnagl, K., Gerner, C., Löw‐Baselli, A., Rossmanith, W., Parzefall, W., & Schulte‐Hermann, R. (2002) · Hepatology · doi:10.1053/jhep.2002.33203 · Cited by 32
Optimization of a synthetic $beta;-catenin-dependent promoter for tumor-specific cancer gene therapy
Lipinski, K. S., Djeha, H., Gawn, J. M., Cliffe, S., Maitland, N. J., Palmer, D. H., Mountain, A., Irvine, A. S., & Wrighton, C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.03.021 · Cited by 31
Nagata, K., Hirono, S., Ido, A., Kataoka, H., Moriuchi, A., Shimomura, T., Hori, T., Hayashi, K., Koono, M., Kitamura, N., et al. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5916 · Cited by 30
Longerich, T., Breuhahn, K., Odenthal, M., Petmecky, K., & Schirmacher, P. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1118-x · Cited by 30
Self-citationUeno, Y., Sakurai, H., Matsuo, M., Choo, M., Koizumi, K., & Saiki, I. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602548 · Cited by 28
Expression of insulin‐like growth factor II mRNA in hepatocellular carcinoma
Ng, I. O., Lee, J. M. F., Srivastava, G., et al. (1998) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1998.tb00630.x · Cited by 28
Zhang, J., Wang, W., Li, Q., & Qiao, Q. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i6.830 · Cited by 27
Lee, Y. I., Han, Y. J., Lee, S. Y., Lee, Y. I., Park, S. K., Park, Y. J., Moon, H. B., Shin, J. H., & Lee, J. H. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(03)00117-5 · Cited by 27
Musch, A., Rabe, C., Paik, M., Berna, M. J., Schmitz, V., Hoffmann, P., Nischalke, H. D., Sauerbruch, T., & Caselmann, W. H. (2005) · Digestion · doi:10.1159/000084523 · Cited by 24
Saeki, A., Tamura, S., Ito, N., Kiso, S., Matsuda, Y., Yabuuchi, I., Kawata, S., & Matsuzawa, Y. (2000) · Cancer · Cited by 21
Kim, J. H., & Rho, H. M. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1014477218369 · Cited by 15
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“%) present with abnormal AFP serum levels, a fact that has been recently correlated with a molecular subclass of aggressive HCCs (S2 class, EpCAM positive) [77–79].”
BackgroundInfluentialWNT signalling pathways as therapeutic targets in cancer
Anastas, J. N., & Moon, R. T. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3419 · Cited by 1,911
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Molecular targeted therapies in hepatocellular carcinoma†
Llovet, J. M., & Bruix, J. (2008) · Hepatology · doi:10.1002/hep.22506 · Cited by 1,004
Metadata
- Authors
- Breuhahn, K., Longerich, T., & Schirmacher, P.
- Venue
- Oncogene
- Published
- 2006-06-26
- Volume
- 25
- Issue
- 27
- Pages
- 3787-3800
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2050637252
- Cited by
- 391
- References
- 193
- FWCI
- 20.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.